Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes

What Was Tested

This randomized controlled trial looks at Insulin Lispro and Glucagon.

The researchers have evaluated the effect of insulin lispro (Humalog) versus regular human insulin (Humulin R) on the hepatic glucose production (HGP) response to glucagon in type 1 diabetic patients on intensive insulin therapy with continuous subcutaneous insulin infusion (CSII).

Who Took Part

The age groups tagged for this paper are adults, both men and women.

Eight nondiabetic people served as control subjects.

How the Study Was Run

The researchers set it up as a randomized, double-blind and crossover study.

Random assignment meant chance, not the researchers, decided who got Insulin Lispro and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Insulin Lispro, so expectations could not easily colour the readings.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Diabetes Mellitus, Type 1, Glucagon, Gluconeogenesis, Glycated Hemoglobin, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Lispro and Glucagon.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page and the Glucagon compound page, all human trials.